军事飞行人员高血压病带药飞行的探讨

Flying safety in military pilots with hypertension using antihypertensive drug

  • 摘要:
      背景  高血压病是飞行人员的常见病,现阶段临床缺乏军事飞行人员带药飞行的安全性评估及研究。
      目的  探讨高血压病飞行人员带药飞行的安全性及航空医学鉴定。
      方法  选取2010 - 2018年于东部战区空军医院住院的28例男性高血压病飞行人员,年龄31~54岁,机种包括运输机、轰炸机和直升机。确定纳入患者的心血管危险因素和靶器官损害,进行心血管疾病风险分层,并以此为依据进行治疗。血压达标后进行临床生理学检查及飞行能力评估,并进行带药飞行的临床观察。
      结果  28例服用培哚普利、缬沙坦、氢氯噻嗪或苯磺酸氨氯地平的飞行人员,血压控制正常后地面观察3~6个月,经检查和评估合格后参加飞行,并严密观察到2019年12月,随访飞行时间100~3 000 h,均飞行耐力良好,11例已随访至飞行最高年限。
      结论  患高血压病的非高性能飞机飞行人员应用降压药物参加飞行安全可行。

     

    Abstract:
      Background  Hypertension is a common disease among pilots. However, limited clinical evaluation and reseach on flying safety in military pilots using antihypersive drug have been performed.
      Objective  To study flying safety of pilots with hypertension using antihypertensive drug and perform an aviation medical evaluation.
      Methods  Twenty eight pilots with hypertension who admitted to the Air Force Hospital of Eastern Theater Command from 2010 to 2018 were enrolled in our study. Cardiac risk and target organ damage were assessed, and they were treated according to different cardiac risk stratification. When blood pressure was controlled, clinical physiology and flight ability were assessed. Then, they were followed up for clinical observation after qualified for flying.
      Results  The pilots were all male, aged 31-54 years old. The types of aircraft included transporter, bomber and helicopter. After taking perindopril, valsartan, dihydrochlorothiazide, or amlodipine besylate, the pilots’ blood pressure returned to normal range. After 3 to 6 months temporary grounding observation, they were qualified for flying and followed up for clinical observation until December 2019, with a follow-up flight time of 100-3000 hours. Their flight endurances were good. Eleven cases had been followed up to their upper age limits for flying.
      Conclusion  It is feasible to use antihypertensive drugs for pilots with hypertension in non-high performance aircraft.

     

/

返回文章
返回